| Catherine Zepeda, MD | |
|
301 University Blvd, Galveston, TX 77555-5302 | |
| (409) 772-0770 | |
| (409) 747-4010 |
| Full Name | Catherine Zepeda |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 301 University Blvd, Galveston, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003553447 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | BP10080788 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Catherine Zepeda, MD 301 University Blvd, Galveston, TX 77555-5302 Ph: (409) 772-0770 | Catherine Zepeda, MD 301 University Blvd, Galveston, TX 77555-5302 Ph: (409) 772-0770 |
News Archive
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.
Although the measure must be passed in order to avert a government shutdown, some Republicans are frustrated because they say the bill does not go far enough in terms of spending cuts, and because it does not include controversial riders to defund the health law and Planned Parenthood.
InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to research proprietary technologies developed by InNexus.
Cancer cells spread to other sites in the body through promoting the growth of new 'roads' to travel on.
Gynesonics, a women's healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its Sonata Sonography-Guided Transcervical Fibroid Ablation (Sonata) System.
› Verified 8 days ago
Dr. Camila Narvaez Caicedo, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 301 University Blvd # 9.128, Galveston, TX 77555 Phone: 409-772-8031 Fax: 409-772-6940 | |
Joan R Hebeler I, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-772-2222 | |
Dr. Chilvana V Patel, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-772-2222 Fax: 409-772-4456 | |
James Clynes, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 301 University Blvd., Galveston, TX 77555 Phone: 409-772-0770 Fax: 409-747-4010 | |
Sarghi Sharma, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-772-2222 | |
Dr. Paymon Behrooz Mosavi, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-772-0770 Fax: 409-747-4010 |